Wen Zijun, Liu Xing, Zhong Yingqi, Zhou Haier, Xiao Guoming, Huang Zhongying, Chen Lihui
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Nutr. 2025 Jun 25;12:1521239. doi: 10.3389/fnut.2025.1521239. eCollection 2025.
This retrospective study aimed to study the effects of percutaneous endoscopic gastrostomy (PEG) on nutritional status and overall survival (OS) of cervical esophageal cancer (CEC) patients who received concurrent chemoradiotherapy.
Thirty-four CEC patients who underwent concurrent chemoradiotherapy (CCRT) were retrospectively reviewed. A series of nutritional indicators: controlling nutritional status (CONUT) score, weight, body mass index, albumin, lymphocyte counts, hemoglobin (HGB) was introduced to evaluate the nutritional status between patients with or without PEG.
Among the 34 patients, 18 received PEG placement (PEG group) and 16 did not (Non-PEG group). The median survival for the PEG group was 38.0 months (range, 6.0-60.3), and for the Non-PEG group, it was 43.5 months (range, 21.5-162.8). The 2, 3, and 4 year OS rates for the PEG group were 81.9% (95% confidence interval [CI]: 63.2-100%), 54.3% (95% CI: 25.5-83.1%), and 32.6% (95% CI: 0.0-63.6%), respectively, while the Non-PEG group had 2, 3, and 4 year OS rates of 100% (95% CI: 83.0-100%), 82.1% (95% CI: 59.2-100%), and 49.2% (95% CI: 11.4-87.0%), respectively. There was no significant difference in the OS between the PEG group and the Non-PEG group ( = 0.095, hazard ratio [HR] 0.398, 95% [CI] 0.135-1.173). In the nutritional index, changes in HGB were significantly correlated with PEG ( = 0.016). Multivariate analysis results showed: weight loss ≥5% ( = 0.041, HR = 5.664, 95% CI: 1.075-29.846) and a CONUT score ≥4 ( = 0.01, HR = 15.223, 95% CI: 1.935-119.783) were independent prognostic factors for OS.
Weight loss during chemoradiotherapy and higher CONUT scores may decrease the OS rate for CEC patients. However, PEG insertion did not affect the OS rate.
本回顾性研究旨在探讨经皮内镜下胃造口术(PEG)对接受同步放化疗的颈段食管癌(CEC)患者营养状况和总生存期(OS)的影响。
回顾性分析34例行同步放化疗(CCRT)的CEC患者。引入一系列营养指标:控制营养状况(CONUT)评分、体重、体重指数、白蛋白、淋巴细胞计数、血红蛋白(HGB),以评估有无行PEG患者之间的营养状况。
34例患者中,18例行PEG置入术(PEG组),16例未行(非PEG组)。PEG组的中位生存期为38.0个月(范围6.0 - 60.3个月),非PEG组为43.5个月(范围21.5 - 162.8个月)。PEG组的2年、3年和4年总生存率分别为81.9%(95%置信区间[CI]:63.2 - 100%)、54.3%(95% CI:25.5 - 83.1%)和32.6%(95% CI:0.0 - 63.6%),而非PEG组的2年、3年和4年总生存率分别为100%(95% CI:83.0 - 100%)、82.1%(95% CI:59.2 - 100%)和49.2%(95% CI:11.4 - 87.0%)。PEG组和非PEG组的总生存期无显著差异( = 0.095,风险比[HR] 0.398,95%[CI] 0.135 - 1.173)。在营养指标方面,HGB的变化与PEG显著相关( = 0.016)。多因素分析结果显示:体重减轻≥5%( = 0.041,HR = 5.664,95% CI:1.075 - 29.846)和CONUT评分≥4( = 0.01,HR = 15.223,95% CI:1.935 - 119.783)是总生存期的独立预后因素。
同步放化疗期间体重减轻和较高的CONUT评分可能会降低CEC患者的总生存率。然而,PEG置入术并不影响总生存率。